These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31132474)

  • 21. Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.
    Blanchard AC; Rooney AM; Yau Y; Zhang Y; Stapleton PJ; Horton E; Klingel M; Stanojevic S; Ratjen F; Coburn B; Waters V
    J Cyst Fibros; 2018 Nov; 17(6):723-728. PubMed ID: 29525410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
    Mayer-Hamblett N; Kronmal RA; Gibson RL; Rosenfeld M; Retsch-Bogart G; Treggiari MM; Burns JL; Khan U; Ramsey BW;
    Pediatr Pulmonol; 2012 Feb; 47(2):125-34. PubMed ID: 21830317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.
    Vidya P; Smith L; Beaudoin T; Yau YC; Clark S; Coburn B; Guttman DS; Hwang DM; Waters V
    Eur J Clin Microbiol Infect Dis; 2016 Jan; 35(1):67-74. PubMed ID: 26492874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
    Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
    Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.
    West SE; Zeng L; Lee BL; Kosorok MR; Laxova A; Rock MJ; Splaingard MJ; Farrell PM
    JAMA; 2002 Jun; 287(22):2958-67. PubMed ID: 12052125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis.
    Nayir Buyuksahin H; Yalçın E; Emiralioglu N; Hazırolan G; Ademhan Tural D; Ozsezen B; Sunman B; Guzelkas I; Dogru D; Ozcelik U; Kiper N
    Pediatr Int; 2022 Jan; 64(1):e15249. PubMed ID: 36321341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.
    Heltshe SL; Khan U; Beckett V; Baines A; Emerson J; Sanders DB; Gibson RL; Morgan W; Rosenfeld M
    J Cyst Fibros; 2018 May; 17(3):341-347. PubMed ID: 29110966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Viel M; Hubert D; Burgel PR; Génin E; Honoré I; Martinez B; Gaitch N; Chapron J; Kanaan R; Dusser D; Girodon E; Bienvenu T
    Clin Respir J; 2016 Nov; 10(6):777-783. PubMed ID: 25763772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
    Jain K; Wainwright C; Smyth AR
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009530. PubMed ID: 24363033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study.
    Ratjen F; Moeller A; McKinney ML; Asherova I; Alon N; Maykut R; Angyalosi G;
    J Cyst Fibros; 2019 Jan; 18(1):78-85. PubMed ID: 29685813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Ratjen F
    Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK
    Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.